A Trump administration plan to lower drug costs for seniors on Medicare could end up forcing seniors to pay hundreds of dollars more for their arthritis medication, according to a new analysis.
The pharma-funded study from the consulting firm Avalere Health found that Medicare patients with rheumatoid arthritis could pay more for their drugs due to a proposal in the administration’s blueprint released last May to tackle high drug prices.
In-depth coverageas the midterms
take shape.
Follow the latest midterm news, analysis, and expert perspectives with unlimited access.
See Subscription Options
Already a member? Log in
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.